Intellia Therapeutics (NTLA) Tops Q3 EPS by 9c
Tweet
Share
E-mail
Get Alerts NTLA Hot Sheet
Join SI Premium – FREE
Intellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.92), $0.09 better than the analyst estimate of ($1.01). Revenue for the quarter came in at $13.78 million versus the consensus estimate of $14.06 million.
For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Sony Semiconductor Solutions unveils 64MP mobile image sensor
- Lockheed Martin wins $8.4B missile contract modification
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
